View Older Stories

Feb 25, 2026 07:10AM Cytokinetics (CYTK) PT Raised to $85 at Needham

Dec 22, 2025 07:25AM Cytokinetics (CYTK) PT Raised to $84 at Needham

Mar 31, 2025 04:00PM Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference

May 23, 2024 07:17AM Cytokinetics (CYTK) PT Lowered to $72 at Needham

Apr 1, 2024 04:00PM Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 10, 2023 04:00PM Cytokinetics To Participate In The 22nd Annual Needham Virtual Healthcare Conference

May 5, 2022 06:43AM Cytokinetics (CYTK) PT Raised to $60 at Needham & Company on Higher Price of mavacamten, Focus Remains on omecamtiv PDUFA

Apr 14, 2022 05:46AM Needham & Company Reiterates Buy Rating, $52 Price Target on Cytokinetics (CYTK)

Apr 6, 2022 04:00PM Cytokinetics to Participate in the 21st Annual Needham Virtual Healthcare Conference

Feb 25, 2022 11:26AM Needham & Company Reiterates Buy Rating on Cytokinetics (CYTK) on Q4 Results and Upcoming Catalysts

Feb 16, 2022 06:17AM Needham & Company Reiterates Cytokinetics (CYTK) at Buy, Sees no Impact from METEORIC-HF Fail on Potential FDA Approval

Feb 4, 2022 10:19AM Cytokinetics (CYTK) Reiterated at Buy by Needham & Company on NDA Acceptance, Expect FDA Approval of omecamtiv

Jul 23, 2021 12:45PM Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Jul 21, 2021 05:20AM Cytokinetics (CYTK) Prices 10M Share Offering at $27.5/sh

Jul 20, 2021 11:15PM Cytokinetics Announces Pricing of Public Offering of Common Stock

Jul 19, 2021 11:30AM Cytokinetics (CYTK) PT Raised to $48 at Needham & Company

Apr 5, 2021 04:00PM Cytokinetics to Participate in the 20th Annual Needham Virtual Healthcare Conference

Apr 8, 2020 04:00PM Cytokinetics to Participate in the 19th Annual Needham Virtual Healthcare Conference

Nov 1, 2019 07:29AM Cytokinetics (CYTK) PT Raised to $24 at Needham & Company

Aug 9, 2019 08:57AM Cytokinetics (CYTK) PT Raised to $16 at Needham & Company

Apr 1, 2019 04:00PM Cytokinetics to Present at April Investor Conferences

Mar 5, 2018 04:00PM Cytokinetics to Present at March Investor Conferences

Nov 21, 2017 01:33PM Needham & Company Downgrades Cytokinetics (CYTK) to Buy

May 9, 2017 09:24AM UPDATE: Pre-Open Movers 05/09: (VRX) (NVMI) (ODP) Higher; (SCYX) (HTZ) (NVRO) Lower (more...)

Mar 29, 2017 04:00PM Cytokinetics to Present at the 16th Annual Needham Healthcare Conference

Feb 17, 2017 06:58AM Cytokinetics (CYTK): Transformative VITALITY-ALS Readout on Track - Needham

Feb 6, 2017 09:30AM Pre-Open Movers 02/06: (GALE) (HAS) (COG) Higher; (TIF) (IP) (BLUE) Lower (more...)

Feb 6, 2017 06:30AM Needham & Company Upgrades Cytokinetics (CYTK) to Strong Buy

Sep 1, 2016 12:45PM Needham & Company Positive on Cytokinetics (CYTK) as Amgen to Move Ahead with Omecamtiv Phase III

Jul 27, 2016 12:23PM Cytokinetics (CYTK) PT Raised to $17 at Needham & Company on Expanding Astellas Collaboration

Apr 5, 2016 04:00PM Cytokinetics to Present at the 15th Annual Needham Healthcare Conference

Apr 16, 2015 01:12PM Needham & Company Highlights Three Under-the-Radar Biotech Stocks (ARGS) (TLOG) (CYTK)

May 7, 2014 08:41AM Cytokinetics (CYTK) a Buy on Partnered Pipeline, Needham & Company Says

Apr 25, 2014 10:50AM Notable Analyst Rating Changes 04/25: (CELG) (SYNA) (WFC) Upgraded; (KLAC) (LLTC) (CYTK) Downgraded

Mar 27, 2014 07:10AM Cytokinetics (CYTK) Has Favorable Risk/Reward Going into TIiasemtiv Data, Needham & Company Says

Oct 11, 2013 12:54PM Unusual 11 Mid-Day Movers 10/11: (SCTY) (LLEN) (CYTK) Higher; (ARIA) (LBIX) (PRKR) Lower

Oct 11, 2013 09:42AM Needham & Company Says Buy Cytokinetics (CYTK) as Market Misread of Omecamtiv Data

Jun 21, 2013 02:54PM Stocks Showing 'Golden Cross' Pattern 06/21: (ABX) (ENDP) (FNSR) (CYTK)

Jun 18, 2013 03:05PM Notable 52-Week Highs and Lows of the Day 06/18: (CYTK) (GE) (SPRD) High; (FIO) (LINE) (PANW) Low

Jun 13, 2013 07:34AM Needham & Company Sees 150% Upside in Cytokinetics (CYTK) after Expanded Amgen (AMGN) Deal

Apr 2, 2013 07:41AM Needham & Company Bullish on Cytokinetics (CYTK) Into Omecamtiv Phase IIb Read-Out Midyear

Jul 2, 2012 07:31AM Needham & Company Starts Cytokinetics (CYTK) at Buy; Well Capitalized to Execute

Jun 3, 2011 08:01AM Needham & Company Maintains a 'Hold' on Cytokinetics (CYTK); Data from Phase 2 “Evidence of Effect” Trial in Claudication Confirm the Rapid Effect of CK-357

Apr 28, 2011 09:13AM Needham & Company maintains a 'Hold' on Cytokinetics (CYTK); Outlines Plans for Product Pipeline

Feb 15, 2011 07:29AM Needham & Company Maintains a 'Hold' on Cytokinetics (CYTK); CK-357 Data in ALS Encouraging, And We Await Study Findings in PVD and MG

Dec 13, 2010 01:15PM Needham & Company on Cytokinetics (CYTK): Phase 2a Data Show Potential of CK-357 to Improve Function in ALS Patients, and Phase 2 Multiple Dose Proof of Concept Planned

Oct 29, 2009 10:55AM Needham & Co Downgrades Cytokinetics (CYTK) to Hold; Lack of Near Term Catalysts

View Older Stories